home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 03/30/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

VANCOUVER, Washington, March 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - CytoDyn May Be One Of The First Biotechs To Have A Drug That Helps Against Covid-19

The respiratory condition that is so dangerous in Covid-19 results from a condition called a "cytokine storm." CytoDyn (CYDY) believes that filling the CCR5 receptor with a harmless monoclonal body will prevent further damage. CytoDyn reported on March 19 that its main drug candidate, lero...

CYDY - Covid-19 activity roundup - healthcare

Sanofi (NASDAQ: SNY ) and Translate Bio (NASDAQ: TBIO ) add an mRNA vaccine for COVID-19 to their 2018 collaboration aimed at developing vaccines for infectious diseases. TBIO has begun producing multiple mRNA constructs and will use its mRNA platform to design and manufacture a range of c...

CYDY - CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CYDY - Best Penny Stocks To Buy After Fed's Aggressive Move?

Are These The Best Penny Stocks To Buy Right Now Or Should They Be Avoided All Together? On Monday morning, the markets rebounded in an aggressive fashion. But this is a stark difference in what we saw late last night with stock market futures hitting the “limit down”. This week&...

CYDY - Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients

VANCOUVER, Washington, March 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - CytoDyn: Leronlimab Deployed To The Frontlines Against Coronavirus

CytoDyn ( CYDY ) continues to expand leronlimab’s programs and has decided to take on the coronavirus “COVID-19” pandemic. Recently, the company reported that its emergency IND has been accepted and has already dosed two patients in NYC. The company has been promoting ...

CYDY - U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn's Leronlimab

VANCOUVER, Washington, March 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CYDY - CytoDyn to Present at Wall Street Reporter's NEXT SUPER STOCK -  Live Stream Event on March 19, 2020

VANCOUVER, Washington, March 18, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, ann...
Previous 10 Next 10